Formation and glomerular deposition of immune complexes in mice administered bovine serum albumin: Evaluation of dose, frequency, and biomarkers

References

• Alpers J, Steward M, Soothill J. 1972. Differences in immune elimination in inbred mice. The role of low affinity antibody. Clin Exp Immunol. 12(1):121–132.
   PubMed Web of Science ®Google Scholar
• Arisz L, Noble B, Milgrom M, Brentjens J, Andres G. 1979. Experimental chronic serum sickness in rats. A model of immune complex glomerulonephritis and systemic immune complex deposition. Int Arch Allergy Immunol. 60(1):80–88.
   Web of Science ®Google Scholar
• Bessa J, Boeckle S, Beck H, Buckel T, Schlicht S, Ebeling M, Kiialainen A, Koulov A, Boll B, Weiser T. 2015. The immunogenicity of antibody aggregates in a novel transgenic mouse model. Pharm Res. 32(7):2344–2359.
   PubMed Web of Science ®Google Scholar
• Border W, Kamil E, Ward H, Cohen A. 1981. Antigenic changes as a determinant of immune complex localization in the rat glomerulus. Lab Invest. 45(5):442–449.
   PubMed Web of Science ®Google Scholar
• Boysen L, Lauritzen B, Viuff BM, Lykkesfeldt J, Landsy LH. 2019a. An ELISA for detection of complement-bound circulating immune complexes in mice. J Immunotoxicol. 16(1):82–86.
   PubMed Web of Science ®Google Scholar
• Boysen L, Sprinkel AME, Lauritzen B, Breinholt J, Lykkesfeldt J, Viuff BM, Landsy LH. 2019b. Generic immune complex assay for detection of murine anti-drug antibodies in complex with human IgG. Biologicals. 60:42–48.
   PubMed Web of Science ®Google Scholar
• Braun A, Kwee L, Labow M, Alsenz J. 1997. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon (IFN)-γ in normal and transgenic mice. Pharm Res. 14(10):1472–1478.
   PubMed Web of Science ®Google Scholar
• Brinks V, Jiskoot W, Schellekens H. 2011. Immunogenicity of therapeutic proteins: The use of animal models. Pharm Res. 28(10):2379–2385.
   PubMed Web of Science ®Google Scholar
• Broderson J. 1989. A retrospective review of lesions associated with the use of Freund's adjuvant. Lab Animal Sci. 39(5):400–405.
   PubMedGoogle Scholar
• Bugelski P, Treacy G. 2004. Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans. Curr Opin Mol Ther. 6(1):10–16.
   PubMedGoogle Scholar
• Chen J, Chen A, Chang L, Chang W, Lee H, Lin S, Lin Y. 2004. Mouse model of membranous nephropathy induced by cationic bovine serum albumin: Antigen dose-response relations and strain differences. Nephrol Dial Transplant. 19(11):2721–2728.
   PubMed Web of Science ®Google Scholar
• Devey M, Steward M. 1980. The induction of chronic antigen-antibody complex disease in selectively-bred mice producing either high or low affinity antibody to protein antigens. Immunology. 41(2):303–311.
   PubMed Web of Science ®Google Scholar
• Devey ME, Bleasdale K, Collins M, Steward MW. 1982. Experimental antigen-antibody complex disease in mice. The role of antibody levels, antibody affinity and circulating antigen-antibody complexes. Int Arch Allergy Immunol. 68(1):47–53.
   Web of Science ®Google Scholar
• European Medicines Agency (EMA). 2006. Guideline on immunogenicity assessment of therapeutic proteins. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf
   Google Scholar
• Frazier K, Obert L. 2018. Drug-induced glomerulonephritis: The spectre of biotherapeutic and antisense oligonucleotide immune activation in the kidney. Toxicol Pathol. 46(8):904–917.
   PubMed Web of Science ®Google Scholar
• Frazier K, Engelhardt J, Fant P, Guionaud S, Henry S, Leach M, Louden C, Scicchitano M, Weaver J, Zabka T. 2015. Drug-induced vascular injury associated with non-small molecule therapeutics in preclinical development: part I. Toxicol Pathol. 43(7):915–934.
   PubMed Web of Science ®Google Scholar
• Fukushima A, Yamaguchi T, Ishida W, Fukata K, Taniguchi T, Liu FT, Ueno H. 2006. Genetic background determines susceptibility to experimental immune-mediated blepharoconjunctivitis: Comparison of Balb/c and C57BL/6 mice. Exp Eye Res. 82(2):210–218.
   PubMed Web of Science ®Google Scholar
• Furness P, Turner D. 1988. Chronic serum sickness glomerulonephritis: removal of glomerular antigen and electron-dense deposits is largely dependent on plasma complement. Clin Exp Immunol. 74(1):126–130.
   PubMed Web of Science ®Google Scholar
• Hebert L, Birmingham D, Mahan J, Shen X, McAllister C, Cosio F, Dillon J. 1994. Effect of chronically-increased erythrocyte complement receptors on immune complex nephritis. Kidney Intl. 45(2):493–499.
   PubMed Web of Science ®Google Scholar
• Hebert L, Cosio F, Birmingham D, Mahan J, Sharma H, Smead W, Goel R. 1991. Experimental immune complex-mediated glomerulonephritis in the non-human primate. Kidney Intl. 39(1):44–56.
   PubMed Web of Science ®Google Scholar
• Hogendoorn P, Bruijn J, Gelok E, van den Broek L, Fleuren G. 1990. Development of progressive glomerulosclerosis in experimental chronic serum sickness. Nephrol Dial Transplant. 5(2):100–109.
   PubMed Web of Science ®Google Scholar
• Husar E, Solonets M, Kuhlmann O, Schick E, Piper-Lepoutre H, Singer T, Tyagi G. 2017. Hypersensitivity reactions to obinutuzumab in cynomolgus monkeys and relevance to humans. Toxicol Pathol. 45(5):676–686.
   PubMed Web of Science ®Google Scholar
• ICH S6 (R1) 2011. ICH guideline S6 (R1) - Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Available from: https://database.ich.org/sites/default/files/S6_R1_Guideline_0.pdf
   Google Scholar
• Jiskoot W, Kijanka G, Randolph TW, Carpenter JF, Koulov AV, Mahler H-C, Joubert MK, Jawa V, Narhi LO. 2016. Mouse models for assessing protein immunogenicity: lessons and challenges. J Pharm Sci. 105(5):1567–1575.
   PubMed Web of Science ®Google Scholar
• Kijanka G, Jiskoot W, Schellekens H, Brinks V. 2013. Effect of treatment regimen on the immunogenicity of human IFN-γ in immune-tolerant mice. Pharm Res. 30(6):1553–1560.
   PubMed Web of Science ®Google Scholar
• Koffler D, Biesecker G, Noble B, Andres G, Martinez-Hernandez A. 1983. Localization of the membrane attack complex (MAC) in experimental immune complex glomerulonephritis. J Exp Med. 157(6):1885–1905.
   PubMed Web of Science ®Google Scholar
• Krishna M, Nadler S. 2016. Immunogenicity to biotherapeutics: The role of anti-drug immune complexes. Front Immunol. 7:1–13.
   PubMed Web of Science ®Google Scholar
• Kronenberg S, Husar E, Schubert C, Freichel C, Emrich T, Lechmann M, Giusti AM, Regenass F. 2017. Comparative assessment of immune complex-mediated hypersensitivity reactions with biotherapeutics in the non-human primate: critical parameters, safety and lessons for future studies. Regul Toxicol Pharmacol. 88:125–137.
   PubMed Web of Science ®Google Scholar
• Leach M, Rottman J, Hock M, Finco D, Rojko J, Beyer J. 2014. Immunogenicity/hypersensitivity of biologics. Toxicol Pathol. 42(1):293–300.
   PubMed Web of Science ®Google Scholar
• Lucisano Valim Y, Lachmann P. 1991. The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: A systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clin Exp Immunol. 84(1):1–8.
   PubMed Web of Science ®Google Scholar
• Mannik M. 1980. Physicochemical and functional relationships of immune complexes. J Invest Dermatol. 74(5):333–338.
   PubMed Web of Science ®Google Scholar
• Morokata T, Ishikawa J, Ida K, Yamada T. 1999. C57BL/6 mice are more susceptible to antigen-induced pulmonary eosinophilia than BALB/c mice, irrespective of systemic TH1/TH2 responses. Immunology. 98(3):345–351.
   PubMed Web of Science ®Google Scholar
• Murphy K, and Weaver C. (Eds.). 2016. Janeway's Immunobiology. New York: Garland Science.
   Google Scholar
• Noble B, Milgrom M, van Liew J, Brentjens J. 1981. Chronic serum sickness in the rat: Influence of antigen dose, route of antigen administration and strain of rat on the development of disease. Clin Exp Immunol. 46(3):499–507.
   PubMed Web of Science ®Google Scholar
• Noble B, Olson K, Milgrom M, Albini B. 1980. Tissue deposition of immune complexes in mice receiving daily injections of bovine serum albumin. Clin Exp Immunol. 42(2):255–262.
   PubMed Web of Science ®Google Scholar
• Noble B, Steward M, Vladutiu A, Brentjens J. 1987. Relationship of the quality and quantity of circulating anti-BSA antibodies to the severity of glomerulonephritis in rats with chronic serum sickness. Clin Exp Immunol. 67(2):277–282.
   PubMed Web of Science ®Google Scholar
• Pangburn M, Muller-Eberhard H. 1983. Initiation of the alternative complement pathway due to spontaneous hydrolysis of the thioester of C3. Ann NY Acad Sci. 421(1):291–298.
   PubMedGoogle Scholar
• Peress N, Miller F, Palu W. 1977a. The choroid plexus in passive serum sickness. J Neuropathol Exp Neurol. 36(3):561–566.
   PubMed Web of Science ®Google Scholar
• Peress N, Miller F, Palu W. 1977b. The immunopathophysiological effects of chronic serum sickness on rat choroid plexus, ciliary process and renal glomeruli. J Neuropathol Exp Neurol. 36(4):726–733.
   PubMed Web of Science ®Google Scholar
• Petty R, Steward M, Soothill J. 1972. The heterogeneity of antibody affinity in inbred mice and its possible immuno-pathologic significance. Clin Exp Immunol. 12:231–241.
   PubMed Web of Science ®Google Scholar
• Pierog P, Krishna M, Yamniuk A, Chauhan A, DeSilva B. 2015. Detection of drug-specific circulating immune complexes from in vivo cynomolgus monkey serum samples. J Immunol Meth. 416:124–136.
   PubMed Web of Science ®Google Scholar
• Pilegaard K, Madsen C. 2004. An oral Brown Norway rat model for food allergy: Comparison of age, sex, dosing volume, and allergen preparation. Toxicology. 196(3):247–257.
   PubMed Web of Science ®Google Scholar
• Ponce R, Abad L, Amaravadi L, Gelzleichter T, Gore E, Green J, Gupta S, Herzyk D, Hurst C, Ivens IA, et al. 2009. Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of non-clinical safety studies. Regul Toxicol Pharmacol. 54(2):164–182.
   PubMed Web of Science ®Google Scholar
• Poskitt P, Poskitt T. 1982. Absence of circulating IgG immune complexes in C57Bl/6 mice with age-associated renal IgG deposits. Immunol Commun. 11(2):97–104.
   PubMed Web of Science ®Google Scholar
• Rojas J, Taylor R, Cunningham M, Rutkoski T, Vennarini J, Jang H, Graham M, Geboes K, Rousselle S, Wagner C. 2005. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther. 313(2):578–585.
   PubMed Web of Science ®Google Scholar
• Rojko JL, Evans MG, Price SA, Han B, Waine G, DeWitte M, Haynes J, Freimark B, Martin P, Raymond JT, et al. 2014. Formation, clearance, deposition, pathogenicity, and identification of biopharmaceutical-related immune complexes: Review and case studies. Toxicol Pathol. 42(4):725–764.
   PubMed Web of Science ®Google Scholar
• Saglam F, Celik A, Tayfur D, Cavdar Z, Yilmaz O, Sarioglu S, Kolatan E, Oktay G, Camsari T. 2010. Decrease in cell proliferation by a matrix metalloproteinase inhibitor, doxycycline, in a model of immune-complex nephritis. Nephrology. 15(5):560–567.
   PubMed Web of Science ®Google Scholar
• Sarvas H, Seppala I, Tahtinen T, Peterfy F, Makela O. 1983. Mouse IgG antibodies have subclass-associated affinity differences. Mol Immunol. 20(3):239–246.
   PubMed Web of Science ®Google Scholar
• Schifferli J, Taylor R. 1989. Physiological and pathological aspects of circulating immune complexes. Kidney Intl. 35(4):993–1003.
   PubMed Web of Science ®Google Scholar
• Shankar G, Charles C, Stein K. 2007. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol. 25(5):555–561.
   PubMed Web of Science ®Google Scholar
• Soothill J, Steward M. 1971. The immuno-pathological significance of the heterogeneity of antibody affinity. Clin Exp Immunol. 9:193–199.
   PubMed Web of Science ®Google Scholar
• Steward M, Collins M, Stanley C, Devey M. 1981. Chronic antigen-antibody-complex glomerulonephritis in mice. Br J Exp Pathol. 62(6):614–622.
   PubMedGoogle Scholar
• Stubenrauch K, Mackeben K, Vogel R, Heinrich J. 2012. Generic anti-drug antibody assay with drug tolerance in serum samples from mice exposed to human antibodies. Anal Biochem. 430(2):193–199.
   PubMed Web of Science ®Google Scholar
• Stubenrauch K, Wessels U, Essig U, Vogel R, Schleypen J. 2010. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies. J Pharm Biomed Anal. 52(2):249–254.
   PubMed Web of Science ®Google Scholar
• Thurman J, Ljubanovic D, Edelstein C, Gilkeson G, Holers V. 2003. Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol. 170(3):1517–1523.
   PubMed Web of Science ®Google Scholar
• Tsokos G, Gordon C, Smolen J. (Eds.) 2007. Systemic Lupus Erythematosus: A Companion to Rheumatology. Philadelphia: Mosby Elsevier.
   Google Scholar
• Urizar R, Cerda J, Reilly A. 1989. Glomerulitis induced by cationized bovine serum albumin in the rat. Pediatr Nephrol. 3(2):149–155.
   PubMed Web of Science ®Google Scholar
• US FDA (U.S. Food and Drug Administration). 1997. International Conference on Harmonization: Guidance on Preclinical Safety Evaluation of Biotechnology-derived Pharmaceuticals. Vol. 62. Bethesda: US FDA, pp. 515–519.
   Google Scholar
• van Meer P, Kooijman M, Brinks V, Gispen-de Wied C, Silva-Lima B, Moors E, Schellekens H. 2013. Immunogenicity of mAbs in non-human primates during non-clinical safety assessment. MAbs. 5(5):810–816.
   PubMed Web of Science ®Google Scholar
• Watanabe H, Numata K, Ito T, Takagi K, Matsukawa A. 2004. Innate immune response in TH1- and TH2-dominant mouse strains. Shock. 22(5):460–466.
   PubMed Web of Science ®Google Scholar
• Wu C, Chen J, Lin S, Chen A, Sytwu H, Lin Y. 2008. Experimental model of membranous nephropathy in mice: Sequence of histological and biochemical events. Lab Anim. 42(3):350–359.
   PubMedGoogle Scholar